Update in Endocrinology
Authors: Hunter Heath, Bruce Mitlak, Pamela Anderson
Journal: Annals of Internal Medicine (1999)

Letters17 August 1999Update in EndocrinologyHunter Heath III, MD, Bruce Mitlak, MD, and Pamela Anderson, MDHunter Heath III, MDEli Lilly and Company; Indianapolis, IN 46285 (Heath)Eli Lilly and Company; Indianapolis, IN 46285 (Mitlak)Eli Lilly and Company; Indianapolis, IN 46285 (Anderson)Search for more papers by this author, Bruce Mitlak, MDEli Lilly and Company; Indianapolis, IN 46285 (Heath)Eli Lilly and Company; Indianapolis, IN 46285 (Mitlak)Eli Lilly and Company; Indianapolis, IN 46285 (Anderson)Search for more papers by this author, and Pamela Anderson, MDEli Lilly and Company; Indianapolis, IN 46285 (Heath)Eli Lilly and Company; Indianapolis, IN 46285 (Mitlak)Eli Lilly and Company; Indianapolis, IN 46285 (Anderson)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-131-4-199908170-00012 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We write to correct factual errors in a discussion in the Update in Endocrinology (1) about Eli Lilly and Company's product Evista (raloxifene hydrochloride, 60 mg/d).The statement that “Raloxifene is marketed for postmenopausal women who are at high risk for developing breast cancer” is incorrect. Evista is indicated for the prevention of osteoporosis in postmenopausal women at risk for bone loss, and Lilly markets the product accordingly. The product labeling does not stipulate restriction to use in women at any particular risk for breast cancer. Although it is true that ongoing clinical trials (2, 3) have ...References1. Schlechte JA, Kreisberg R. Update in endocrinology. Ann Intern Med. 1998;129:719-25. LinkGoogle Scholar2. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al . The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999;281:2189-97. CrossrefMedlineGoogle Scholar3. Jordan VC, Glusman JE, Eckert S, Lippman M, Powles T, Costa A, et al. Incident primary breast cancers are reduced by raloxifene: integrated data from multicenter, double-blind, randomized trials in "12,000 postmenopausal women [Abstract]. In: Program/Proceedings of the American Society of Clinical Oncology, Thirty-fourth Annual Meeting, 16-19 May 1998. Philadelphia: W.B. Saunders; 1998:122a. Google Scholar4. Ettinger B, Black D, Cummings S, Genant A, Glüer C, Lips P, et al . Raloxifene reduces the risk of incident vertebral fractures: 24-month interim analyses [Abstract]. Osteoporosis Int. 1998;8 Suppl 3 11. Google Scholar5. Ensrud KE, Harris S, Pols HA, Black D, Recker R, Harris S, et al . The effect of 2 and 3 years of raloxifene on vertebral and non-vertebral fractures in postmenopausal women with osteoporosis [Abstract]. Bone. 1998;23 Suppl 5 S174. Google Scholar Author, Article, and Disclosure InformationAffiliations: Eli Lilly and Company; Indianapolis, IN 46285 (Heath)Eli Lilly and Company; Indianapolis, IN 46285 (Mitlak)Eli Lilly and Company; Indianapolis, IN 46285 (Anderson) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoUpdate in Endocrinology Janet A. Schlechte and Robert Kreisberg Update in Endocrinology Janet A. Schlechte Metrics 17 August 1999Volume 131, Issue 4Page: 309KeywordsBone resorptionBreast cancerCardiovascular disease riskClinical trial reportingClinical trialsCoronary heart diseaseElectrocardiographyEndocrinologyOsteoporosis Issue Published: 17 August 1999 Copyright & PermissionsCopyright © 1999 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...